Adjuvant Therapy With Thalidomide for Chemoembolization in Advanced Hepatocellular Carcinoma
Status:
Unknown status
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
Chemoembolization (TACE) is used in the majority of advanced hepatocellular carcinomas.
Randomized clinical trials indicated that TACE improves overall survival in patients with
good liver function (Child-pugh A or B). However, the shortcoming of TACE is obvious: hypoxia
induced neoangiogenesis after blockage of blood supply of the tumor; repeat TACE deteriorates
liver cirrhosis due to toxicity of chemotherapeutic agent to the parenchyma liver.
Thalidomide has been reported to have antiangiogenic and antimetastatic effects. The
objectives of adjuvant therapy with thalidomide for chemoembolization is to evaluate overall
survival and time to progression.